Have allergies? This EpiPen rival has a list price of $4,500, but most patients won't pay a cent.
CNBC's Meg Tirrell reports Kaleo is bringing back EpiPen competitor Auvi-Q, but that it will be listed at $4,500.
Mallinckrodt is to pay $100 million to settle FTC charges that it illegally maintained a monopoly of a special drug used on infants. CNBC's Meg Tirrell reports.
CNBC's Meg Tirrell reports that Mallinckrodt has settled with the FTC over a potential monopoly situation over one of its drugs.
After a meeting with President-elect Donald Trump, Bayer and Monsanto pledged jobs and investment, but is this spending new? Analysts have their doubts.
According to Trump's transition team, Bayer will commit to $8 billion in new research and development jobs in the U.S. CNBC's Meg Tirrell reports.
Technology has the potential to answer our biggest questions, solve some of our toughest challenges and help us better understand the world around us.
Discussing the current state of the markets with with Meg Green, Meg Green & Associates; Keith Bliss, Cuttone & Co.; and Holly Liss, BTIG.
John Milligan, Gilead president and CEO, speaks to CNBC's Meg Tirrell about potential M&A, drug-pricing pressure under President-elect Donald Trump and the company's hepatitis C drugs.
Mylan CEO Heather Bresch speaks to CNBC's Meg Tirrell about the future of EpiPen pricing under President-elect Donald Trump as he pushes to bring drug prices down.